Table 1. Clinical studies of MSCs in liver diseases.
| Study | Patient group | MSC source | Injection route | Main improvement |
|---|---|---|---|---|
| Mohamadnejad [2007] | Decompensated liver cirrhosis (n=4) | Autologous BM | Peripheral vein | Creatinine and MELD score |
| Kharaziha [2009] | Liver cirrhosis (n=8) | Autologous BM | Portal vein (n=6) | Creatinine, prothrombin time, and MELD score |
| Peripheral vein (n=2) | ||||
| El-Ansary [2010] | Decompensated liver cirrhosis due to HCV or HBV (n=12) | Autologous BM | Intrasplenic (n=6) | Creatinine, prothrombin time, albumin, bilirubin, and MELD score |
| Peripheral vein (n=6) | ||||
| Amer [2011] | Decompensated liver cirrhosis due to HCV (n=40) | Autologous BM | Intrasplenic (n=10) | Ascites, peripheral edema, albumin, MELD score, and Child-Pugh score |
| Intrahepatic (n=10) | ||||
| Peng [2011] | ACLF caused by HBV (n=158) | Autologous BM | Hepatic artery | Prothrombin time, albumin, bilirubin, and MELD score |
| El-Ansary [2012] | Decompensated liver cirrhosis due to HCV (n=25) | Autologous BM | Peripheral vein | Albumin and MELD score |
| Shi [2012] | ACLF-associated HBV (n=43) | Allogeneic UC | Peripheral vein | Albumin, prothrombin time, bilirubin, ALT, survival rates, and MELD score |
| Zhang [2012] | Decompensated liver cirrhosis due to HBV (n=45) | Allogeneic UC | Peripheral vein | Albumin, bilirubin, MELD score, and ascites |
| Amin [2013] | Post-HCV (n=20) | Autologous BM | Intrasplenic | Albumin, prothrombin time, bilirubin, AST, ALT, and MELD score |
| Mohamadnejad [2013] | Decompensated liver cirrhosis (n=25) | Autologous BM | Peripheral vein | None |
| Wang [2013] | UDCA-resistant PBC (n=7) | Allogeneic UC | Peripheral vein | Alkaline phosphatase and γ-glutamyltransferase (GGT) levels |
| Jang [2014] | Alcohol-related liver cirrhosis (n=11) | Autologous BM | Hepatic artery | MELD score and liver histology |
| Salama [2014] | Post-HCV end-stage liver disease (n=40) | Autologous BM | Peripheral vein | MELD score and Child-Pugh score |
| Wang [2014] | UDCA-resistant PBC (n=10) | Allogeneic BM | Peripheral vein | ALT, AST, GGT, and IgM |
| Suk [2016] | Alcohol-related liver cirrhosis (n=72) | Autologous BM | Hepatic artery | Histologic fibrosis and Child-Pugh score |
| Detry [2017] | Liver transplant recipients | Allogenic BM | Peripheral vein | No difference in rate of infection or de novo cancer |
| Lanthier [2017] | Decompensated alcoholic hepatitis (n=58) | Autologous BM | Hepatic artery | None |
| Lin [2017] | ACLF-associated HBV (n=110) | Allogeneic BM | Peripheral vein | Bilirubin, MELD score, and survival rates |
| Liang [2017] | Autoimmune diseases-induced cirrhosis (n=26) | Allogeneic UC (n=23), UCB (n=2), or BM (n=1) | Peripheral vein | Bilirubin, albumin, prothrombin, and MELD score |
| Xu [2019] | ACLF-associated HBV (n=110) | Allogeneic UC | Peripheral vein | Bilirubin, ALT, AST, and MELD score |
ACLF, acute-on-chronic liver failure; BM, bone marrow; HBV, hepatitis B virus; HCV, hepatitis C virus; PBC, primary biliary cholangitis; RCT, randomized controlled trial; UC, umbilical cord; UDCA, ursodeoxycholic acid